Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
LaiKai Pharmaceuticals: Collaborated with Eli Lilly to complete the LAE102 Phase I study in the United States
Lai Kai Pharmaceuticals recently announced that the company has partnered with Eli Lilly to successfully complete a Phase I single-dose escalation study of LAE102 in the United States.
The study aimed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 in healthy postmenopausal women. The average BMI of the enrolled subjects was 26.99 kg/m2. The results indicated that the safety profile was consistent with previous studies, and no serious adverse events were reported.
(Lai Kai Pharmaceuticals Announcement)
(Edited by: Yang Yan, Lin Chen)
Keywords: Medical